A 2-Part First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CMTX-101

Clinical trial NCT05629741 · TERMINATED

Trial details

NCT number: NCT05629741
Sponsor: Clarametyx Biosciences, Inc.
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Community-acquired Pneumonia Bacterial Pneumonia

Start date: 2022-11-14
Primary completion: 2024-08-02
Enrollment: 28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.